Biomarkers in Contrast-Induced Nephropathy: Advances in Early Detection, Risk Assessment, and Prevention Strategies
International Journal of Molecular Sciences · 21.03.2025 · 26 (7) · 2869
DOI: 10.3390/ijms26072869 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 21.03.2025. Verfasst von Pei-Hua Lee und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Imaging, China Medical University Hospital, Taichung 404, Taiwan. Hauptthemen laut MEDLINE: Contrast Media, Biomarkers, Acute Kidney Injury, Kidney Diseases. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 220 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Contrast-induced nephropathy (CIN) represents a significant complication associated with the use of iodinated contrast media (ICM), especially in individuals with preexisting renal impairment. The pathophysiology of CIN encompasses oxidative stress, inflammation, endothelial dysfunction, and hemodynamic disturbances, resulting in acute kidney injury (AKI). Early detection is essential for effective management; however, conventional markers like serum creatinine (sCr) and estimated glomerular filtration rate (eGFR) exhibit limitations in sensitivity and timeliness. This review emphasizes the increasing significance of novel biomarkers in enhancing early detection and risk stratification of contrast-induced nephropathy (CIN). Recent advancements in artificial intelligence and computational analytics have improved the predictive capabilities of these biomarkers, enabling personalized risk assessment and precision medicine strategies. Additionally, we discuss mitigation strategies, including hydration protocols, pharmacological interventions, and procedural modifications, aimed at reducing CIN incidence. Incorporating biomarker-driven assessments into clinical decision-making can enhance patient management and outcomes. Future research must prioritize the standardization of biomarker assays, the validation of predictive models across diverse patient populations, and the exploration of novel therapeutic targets. Utilizing advancements in biomarkers and risk mitigation strategies allows clinicians to improve the safety of contrast-enhanced imaging and reduce the likelihood of renal injury.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Imaging, China Medical University Hospital, Taichung 404, Taiwan.
- Department of Radiology, School of Medicine, China Medical University, Taichung 404, Taiwan.
- Department of Medical Education, Show Chwan Memorial Hospital, Changhua 500, Taiwan.
- Division of Endocrinology, Department of Internal Medicine, China Medical University Hospital, Taichung 404, Taiwan.
- Department of Pathology, Chung Shan Medical University Hospital, Taichung 402, Taiwan.
- Department of Pathology, School of Medicine, Chung Shan Medical University, Taichung 402, Taiwan.
ORCID-Profile: Shao Min Huang, Fatt Yang Chew
Zitieren
APA
Lee, P. H., Huang, S. M., Tsai, Y. C., Wang, Y. T., & Chew, F. Y. (2025). Biomarkers in Contrast-Induced Nephropathy: Advances in Early Detection, Risk Assessment, and Prevention Strategies. International Journal of Molecular Sciences, 26(7), 2869. https://doi.org/10.3390/ijms26072869
Vancouver
Lee PH, Huang SM, Tsai YC, Wang YT, Chew FY. Biomarkers in Contrast-Induced Nephropathy: Advances in Early Detection, Risk Assessment, and Prevention Strategies. International Journal of Molecular Sciences. 2025;26(7):2869. doi:10.3390/ijms26072869
BibTeX
@article{Lee2025,
author = {Lee, Pei-Hua and Huang, Shao Min and Tsai, Yi-Ching and Wang, Yu-Ting and Chew, Fatt Yang},
title = {Biomarkers in Contrast-Induced Nephropathy: Advances in Early Detection, Risk Assessment, and Prevention Strategies},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {7},
pages = {2869},
doi = {10.3390/ijms26072869}
}
EUVIMED